A clinical briefing on the 2026 Fluticasone/Salmeterol shortage for providers — timeline, alternatives, prescribing strategies, and patient tools.
If your patients have been reporting difficulty filling their Fluticasone/Salmeterol prescriptions, the problem is real. Supply disruptions affecting several formulations of this widely prescribed ICS/LABA combination inhaler have persisted into 2026, creating challenges for clinical management of asthma and COPD patients across practice settings.
This briefing covers the current shortage status, prescribing implications, therapeutic alternatives, and tools to help your patients access their medications.
Fluticasone/Salmeterol supply disruptions first gained significant attention when generic dry powder inhaler products entered the market in 2019 with the FDA approval of Wixela Inhub (Viatris). While generics expanded access and lowered costs, the complex manufacturing requirements for inhaler devices meant that supply has been intermittently constrained since then.
Key milestones:
The shortage creates several clinical considerations:
When a patient's specific inhaler product is unavailable, clinicians must determine whether an equivalent substitution exists or whether a therapeutic switch is warranted.
When switching between Fluticasone/Salmeterol products or to alternative ICS/LABA combinations, dose equivalency is critical. Approximate ICS equivalencies for common alternatives:
These are approximate equivalencies. Clinical judgment should guide dosing decisions based on individual patient response and disease severity.
Inhaler shortages directly threaten adherence. Patients who cannot fill their prescriptions may:
Proactive communication about the shortage and available alternatives can help mitigate these risks.
The shortage has affected formulations unevenly:
Providers can direct patients to Medfinder for Providers to check real-time pharmacy-level stock data for Fluticasone/Salmeterol formulations.
Pricing remains a factor in clinical decision-making, particularly when recommending alternatives:
For commercially insured patients, the GSK Copay Assistance Program can reduce Advair costs to as low as $10/month. The Viatris Wixela Inhub Savings Card offers similar copay reductions (as low as $10/fill, max $50/fill savings). Neither program is available to government-insured patients.
Patient assistance programs (GSK For You, Viatris PAP, NeedyMeds, RxAssist) are available for uninsured and underinsured patients. A detailed breakdown is available in our provider's guide to helping patients save on Fluticasone/Salmeterol.
When Fluticasone/Salmeterol is unavailable, the following ICS/LABA alternatives warrant consideration:
For patient-facing information on alternatives, refer patients to our post on alternatives to Fluticasone/Salmeterol.
The inhaler market continues to evolve. Additional generic entrants may ease supply constraints over time, though the technical barriers to inhaler manufacturing remain high. The growing availability of generic Budesonide/Formoterol (Symbicort) provides an important safety valve for patients who cannot access Fluticasone/Salmeterol.
Telehealth has also expanded access to prescriber consultations, making it easier for patients in underserved areas to get prescriptions adjusted. Encouraging patients to use digital tools for stock checking and appointment scheduling can reduce the burden on practice staff.
The Fluticasone/Salmeterol shortage requires providers to be proactive — anticipating fill failures, discussing backup plans with patients, and staying current on available formulations and alternatives. Tools like Medfinder for Providers can integrate naturally into your workflow, helping you direct patients to pharmacies with confirmed stock rather than sending them on a frustrating search.
For patient-facing resources, consider sharing these links with your patients:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
